Veracyte, Inc. launches the Decipher Prostate Test, now the only gene expression test recommended in NCCN Prostate Cancer Guidelines.
Dec 05, 2024
South San FranciscoBiotechnologyHealth CareArtificial IntelligenceGeneticsHealth Diagnostics
Product Description
Veracyte, Inc. has announced that its Decipher Prostate Genomic Classifier is the only gene expression test included in the updated NCCN Clinical Practice Guidelines for prostate cancer. The test is designed to help clinicians assess the risk of prostate tumor progression.
Company Information
Company
Veracyte
Location
South San Francisco, California, United States
About
Veracyte, Inc. is a leading cancer diagnostics company specializing in transforming cancer care through high-performing tests. With a focus on genomics and clinical data, Veracyte empowers clinicians to make informed treatment decisions. Their products, especially the Decipher Prostate test, are designed to assist in assessing cancer progression risk. The company's innovative diagnostics platform is supported by deep bioinformatics and AI capabilities.
Fundz sees it the moment Veracyte ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoBiotechnologyHealth CareArtificial IntelligenceGeneticsHealth Diagnostics